UBC researchers awarded $1M Wall Fellowships to advance human and ecosystem health - UBC News

The Simons Foundation’s Life Sciences division is now accepting applications for its Simons Postdoctoral Fellowships in Plant Biology. The application deadline is December 3, 2026, at 12 p.m. (noon) EDT. These postdoctoral fellowships support candidates who intend to pursue a career in basic research on fundamental problems in plant biology. This program supports researchers seeking to understand the inner workings of plants at the level of the whole organism or below. We are interested in applicants with training in disciplines that can be brought to bear on plant biology, including but not limited to engineering, computational modeling, theory, chemistry, synthetic biology and physics, as well as applicants already involved in the plant sciences.

VANCOUVER, BC – October 7, 2026 – The Asia Pacific Foundation of Canada is pleased to announce its two Media Fellowship recipients for 2026-27. The annual APF Canada Media Fellowship Program offers Canadian journalists the opportunity to spend time in Asia researching and preparing stories for Canadian audiences. The goal of the program is to help Canadian journalists become better informed about this dynamic part of the world in order to write and broadcast insightfully on Asia and the Canada-Asia relationship.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.